As expected, FDA spikes down Axsome migraine med, but issues are 'addressable'

The FDA has rejected Axsome Therapeutic’s migraine med, an expected result after the company disclosed last week that issues with its chemistry, manufacturing, and controls (CMC) had been deemed unresolved by regulators.